In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with atopic dermatitis after an inadequate response to topical treatment. The choice is therefore large – making the question of subjective and objective decision criteria all the more important.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Update on diagnostics, risk stratification and therapy
Acute myeloid leukemia 2025
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Findings from the TRACK-FA study
Neuroimaging biomarkers in Friedreich’s ataxia
- Doing sport without fear or risk
Doing sport without fear or risk
- Chronic inducible urticaria
What has stayed the same, what has changed?
- National Health Report 2025
Mental health in Switzerland
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Prevention of skin cancer